Answers are grounded in this paper and cite their sources.
This observational study evaluates the efficacy and safety of upadacitinib for refractory Crohn’s disease, suggesting it is effective and well-tolerated.
Aims To evaluate the real-world efficacy and safety of advanced combination therapy with upadacitinib (ACT-U) in East Asian patients with refractory Crohn’s disease (CD). Methods This single-center, retrospective, observational study conducted at Yancheng No.1 People’s Hospital (Jiangsu, China) evaluated the efficacy and safety of ACT-U in 26 patients with refractory CD. Participants received ACT-U (upadacitinib + biologics) following inadequate response to ≥1 biologic. Clinical, endoscopic, and biochemical outcomes were assessed at baseline and posttreatment. Safety profiles were monitored throughout the follow-up period to evaluate the risk of adverse events. Results Patients (median age 27.5 years [IQR, 23.3–32.0], median disease duration 4.0 years [3.0–6.0]) received ACT-U for a median of 14.5 weeks [11.0–18.8]. Median HBI decreased from 7 [6–8] to 2 [2–4] ( p < 0.01). All patients achieved clinical response (95% CI: 85.8, 100%), and 91.7% attained remission (95% CI: 73.0, 99.0%). Median SESCD decreased from 15 [13–17] to 1 [0–2], with ( p < 0.01). All patients achieved endoscopic improvement (95% CI: 85.8, 100%), 83.3% achieved remission (95% CI: 62.6, 95.3%), and 45.8% attained healing (95% CI, 25.6, 67.2%). Mild AEs occurred in 23.1% (95% CI, 9.0, 43.6%; acne, gastrointestinal disturbances, mild infections), including one transient semen discoloration case. No severe AEs or surgeries reported. Conclusion ACT-U aligned with the STRIDE-II goals, demonstrating accelerated attainment of short-to-intermediate term endpoints (per STRIDE-II recommendations). Despite limitations, including its retrospective design and small case series, we provide foundational real-world evidence supporting ACT-U as a well-tolerated and effective regimen for refractory CD in EAS patients. Further prospective studies are warranted to validate long-term outcomes, optimize combination strategies, and assess applicability across diverse frameworks.
No takes yet. Share an insight, caveat, or question.
Ye et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: